000			02082 a2200529 4500
005			20250518014513.0
264		0	_c20190415
008			201904s 0 0 eng d
022			_a1471-2407
024	7		_a10.1186/s12885-018-5198-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aMcGuire, William P
245	0	0	_aRandomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. _h[electronic resource]
260			_bBMC cancer _cDec 2018
300			_a1292 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xpharmacology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aCarcinoma, Ovarian Epithelial _xdrug therapy
650	0	4	_aCisplatin _xpharmacology
650	0	4	_aConstipation _xchemically induced
650	0	4	_aDoxorubicin _xanalogs & derivatives
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFatigue _xchemically induced
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aMucositis _xchemically induced
650	0	4	_aNausea _xchemically induced
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPolyethylene Glycols _xpharmacology
650	0	4	_aProgression-Free Survival
650	0	4	_aReceptor, Platelet-Derived Growth Factor alpha _xantagonists & inhibitors
650	0	4	_aTime Factors
700	1		_aPenson, Richard T
700	1		_aGore, Martin
700	1		_aHerraez, Antonio Casado
700	1		_aPeterson, Patrick
700	1		_aShahir, Ashwin
700	1		_aIlaria, Robert
773	0		_tBMC cancer _gvol. 18 _gno. 1 _gp. 1292
856	4	0	_uhttps://doi.org/10.1186/s12885-018-5198-4 _zAvailable from publisher's website
999			_c29203237 _d29203237